NO20004527L - Modulatorer for proteintyrosinfosfataser (PTPaser) - Google Patents

Modulatorer for proteintyrosinfosfataser (PTPaser)

Info

Publication number
NO20004527L
NO20004527L NO20004527A NO20004527A NO20004527L NO 20004527 L NO20004527 L NO 20004527L NO 20004527 A NO20004527 A NO 20004527A NO 20004527 A NO20004527 A NO 20004527A NO 20004527 L NO20004527 L NO 20004527L
Authority
NO
Norway
Prior art keywords
diseases
compounds
ptpases
protein tyrosine
shp
Prior art date
Application number
NO20004527A
Other languages
English (en)
Other versions
NO20004527D0 (no
Inventor
Niels Peter Hundahl Moeller
Henrik Sune Andersen
Lars Fogh Iversen
Ole Hvilsted Olsen
Sven Branner
Daniel Dale Holsworth
Farid Bakir
Luke Milburn Judge
Frank Urban Axe
Todd Kevin Jones
William Charles Ripka
Yu Ge
Roy Teruyuki Uyeda
Original Assignee
Novo Nordisk As
Ontogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK1999/000121 external-priority patent/WO1999046267A1/en
Application filed by Novo Nordisk As, Ontogen Corp filed Critical Novo Nordisk As
Publication of NO20004527D0 publication Critical patent/NO20004527D0/no
Publication of NO20004527L publication Critical patent/NO20004527L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrodes Of Semiconductors (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Bipolar Transistors (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Control Of El Displays (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer nye forbindelser, nye preparater, fremgangsmåter for deres anvendelse, og fremgangsmåter for deres fremstilling, hvor slike forbindelser er farmakologisk anvendbare inhibitorer for proteintyrosinfosfataser (PTPaser), slik som PTP1B, CD45, SHP-1, SHP-2, . PTPa, LAR og HePTP, eller lignende. Forbindelsene kan anvendes ved behand- ling av sukkersyke av type I, sukker- syke av type II, forstyrret glukose- toleranse, insulinresistens, fedme, immundysfunksjoner, inkludert auto- immunitetssykdommer med dysfunksjoner i koagulasjonssystemet, allergiske syk- dommer, inkludert astma, osteoporose, proliferative forstyrrelser, inkludert kreft og psoriasis, sykdommer med redusert eller forøkt syntese eller effekter av veksthormon, sykdommer med redusert eller forøkt syntese av hor- moner eller cytokiner som regulerer frigjørelsen av/eller responsen på veksthormon, sykdommer i hjernen, inkludert Alzheimers sykdom og schizo- freni, og infeksiøse sykdommer.
NO20004527A 1998-03-12 2000-09-11 Modulatorer for proteintyrosinfosfataser (PTPaser) NO20004527L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DK34498 1998-03-12
DK48098 1998-04-03
DKPA199800938 1998-07-15
DKPA199801385 1998-10-28
DKPA199801612 1998-12-07
PCT/DK1999/000121 WO1999046267A1 (en) 1998-03-12 1999-03-11 Modulators of protein tyrosine phosphatases (ptpases)

Publications (2)

Publication Number Publication Date
NO20004527D0 NO20004527D0 (no) 2000-09-11
NO20004527L true NO20004527L (no) 2000-11-07

Family

ID=27512769

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004527A NO20004527L (no) 1998-03-12 2000-09-11 Modulatorer for proteintyrosinfosfataser (PTPaser)

Country Status (13)

Country Link
EP (1) EP1080095B1 (no)
JP (1) JP2002506072A (no)
KR (1) KR20010041814A (no)
CN (1) CN1300291A (no)
AT (1) ATE308546T1 (no)
AU (1) AU2713599A (no)
BR (1) BR9908726A (no)
CA (1) CA2323493A1 (no)
DE (1) DE69928100D1 (no)
HU (1) HUP0104984A3 (no)
IL (1) IL138319A0 (no)
NO (1) NO20004527L (no)
PL (1) PL342816A1 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002049632A1 (en) 2000-12-18 2002-06-27 Institute Of Medicinal Molecular Design. Inc. Inhibitors against the production and release of inflammatory cytokines
EA009523B1 (ru) * 2002-06-05 2008-02-28 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Ингибиторы в отношении активации ар-1 и nfat
CA2488342A1 (en) * 2002-06-05 2003-12-18 Institute Of Medicinal Molecular Design, Inc. Therapeutic drug for diabetes
US7626042B2 (en) 2002-06-06 2009-12-01 Institute Of Medicinal Molecular Design, Inc. O-substituted hydroxyaryl derivatives
AU2003242103A1 (en) 2002-06-06 2003-12-22 Institute Of Medicinal Molecular Design, Inc Antiallergic agents
EP1753512B1 (en) * 2004-05-28 2008-07-09 Nycomed GmbH Tetrahydropyridothiophenes
DE602005007220D1 (de) * 2004-06-04 2008-07-10 Nycomed Gmbh Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
JP2008501768A (ja) * 2004-06-11 2008-01-24 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の化合物及びテトラヒドロピリドチオフェンの使用
CA2881078C (en) * 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
CA2596202A1 (en) * 2005-02-09 2006-08-17 Altana Pharma Ag Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer
JP2008530053A (ja) * 2005-02-11 2008-08-07 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌の治療のための抗増殖性剤としてのテトラヒドロピリドチオフェン
EP1926737B1 (en) * 2005-09-15 2017-03-15 F. Hoffmann-La Roche AG 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives
CN1939922B (zh) * 2005-09-27 2010-10-13 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物
CN104193761B (zh) * 2009-12-04 2017-10-17 桑诺维恩药品公司 多环化合物及其使用方法
CN102382076B (zh) * 2010-09-03 2016-08-17 中国医学科学院药物研究所 芳酮和芳酰胺类化合物及其制法和药物用途
CN102838625B (zh) * 2011-06-22 2015-04-15 中国科学院上海药物研究所 四氢吡啶并噻唑类化合物、其制备方法、包含该化合物的药物组合物及其用途
US9682967B2 (en) 2013-01-28 2017-06-20 H. Lundbeck A/S N-substituted-5-substituted phthalamic acids as sortilin inhibitors
CN104788424A (zh) * 2015-03-12 2015-07-22 佛山市赛维斯医药科技有限公司 含烟酸酰胺和哌啶结构的ptp1b抑制剂、制备方法及其用途
CN104725306A (zh) * 2015-03-12 2015-06-24 佛山市赛维斯医药科技有限公司 一类含烟酸酰胺结构的ptp1b抑制剂、制备方法及其用途
CN104725308A (zh) * 2015-03-12 2015-06-24 佛山市赛维斯医药科技有限公司 含烟酸酰胺结构的ptp1b抑制剂、制备方法及其用途
CN104788425A (zh) * 2015-03-12 2015-07-22 佛山市赛维斯医药科技有限公司 一类含烟酸酰胺和哌啶结构ptp1b抑制剂、制备方法及其用途
CN104829629B (zh) * 2015-03-26 2017-03-15 天津药物研究院有限公司 含磺酰胺基的四氢噻吩并[2,3‑c]吡啶衍生物、其制备方法和用途
BR112019001407A2 (pt) 2016-07-29 2019-07-09 Sunovion Pharmaceuticals Inc. compostos e composições e usos dos mesmos
SG10202100724UA (en) 2016-07-29 2021-03-30 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
EP3582815A1 (en) 2017-02-16 2019-12-25 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
MX2020000523A (es) 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Compuestos de isocromano y usos de los mismos.
SG11202007823PA (en) 2018-02-16 2020-09-29 Sunovion Pharmaceuticals Inc Salts, crystal forms, and production methods thereof
JP7703449B2 (ja) 2019-03-14 2025-07-07 スミトモ・ファーマ・アメリカ・インコーポレイテッド イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
US12410191B2 (en) 2019-05-21 2025-09-09 Zhejiang Hisun Pharmaceutical Co., Ltd. Macrolide derivatives, preparation method and application thereof
KR20230003503A (ko) 2020-04-14 2023-01-06 선오비온 파마슈티컬스 인코포레이티드 신경학적 및 정신의학적 장애의 치료를 위한 (S)-(4,5-디히드로-7H-티에노[2,3-c]피란-7-일)-N-메틸메탄아민
CN118290333A (zh) * 2020-04-14 2024-07-05 普渡研究基金会 新型淋巴特异性酪氨酸磷酸酶（lyp）抑制剂

Also Published As

Publication number Publication date
HUP0104984A3 (en) 2003-07-28
KR20010041814A (ko) 2001-05-25
PL342816A1 (en) 2001-07-02
BR9908726A (pt) 2000-11-21
DE69928100D1 (de) 2005-12-08
EP1080095B1 (en) 2005-11-02
CN1300291A (zh) 2001-06-20
IL138319A0 (en) 2001-10-31
EP1080095A1 (en) 2001-03-07
JP2002506072A (ja) 2002-02-26
AU2713599A (en) 1999-09-27
HUP0104984A2 (hu) 2002-04-29
ATE308546T1 (de) 2005-11-15
CA2323493A1 (en) 1999-09-16
NO20004527D0 (no) 2000-09-11

Similar Documents

Publication Publication Date Title
NO20004527D0 (no) Modulatorer for proteintyrosinfosfataser (PTPaser)
Vallés et al. Chronic ethanol treatment enhances inflammatory mediators and cell death in the brain and in astrocytes
Cheng et al. Tumor necrosis factors protect neurons against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis
Su et al. Electroacupuncture reduces the expression of proinflammatory cytokines in inflamed skin tissues through activation of cannabinoid CB 2 receptors
Park et al. Increased OPG/RANKL ratio in the conditioned medium of soybean-treated osteoblasts suppresses RANKL-induced osteoclast differentiation
Miwa et al. Lipopolysaccharide enhances synthesis of brain‐derived neurotrophic factor in cultured rat microglia
Majka et al. Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization
AU2002329540A1 (en) Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
BR9912448A (pt) Composto, composição farmacêutica, e, processos de indução de biossìntese de citoquina em um mamìfero, de tratamento de uma doença virótica em um mamìfero, e de tratamento de uma doença neoplásica em um mamìfero
IL170866A (en) A low-fouling liquid preparation containing antibody against ige
BR0206985A (pt) Anticorpos modificados e métodos de uso
Calkins et al. Differential effects of recombinant interleukin-1α and β on Leydig cell function
BRPI0407446A (pt) Anticorpos para c-met para o tratamento de cânceres
ATE266675T1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
Chowdhury et al. Dynamic compression counteracts IL-1β induced inducible nitric oxide synthase and cyclo-oxygenase-2 expression in chondrocyte/agarose constructs
Li et al. Hedgehog signaling is involved in the BMP9-induced osteogenic differentiation of mesenchymal stem cells
Jurado et al. Effect of IL‐1β, PGE2, and TGF‐β1 on the expression of OPG and RANKL in normal and osteoporotic primary human osteoblasts
AU5896098A (en) Inhibitors of interleukin-1beta converting enzyme
Kim et al. 3-Deoxysappanchalcone promotes proliferation of human hair follicle dermal papilla cells and hair growth in C57BL/6 mice by modulating WNT/β-Catenin and STAT signaling
BRPI0414793A (pt) uso do fator anti-secretor
Zhou et al. TRESK gene recombinant adenovirus vector inhibits capsaicin-mediated substance P release from cultured rat dorsal root ganglion neurons
Deb et al. Estrogen regulates expression of tumor necrosis factor receptors in breast adipose fibroblasts
Li et al. Expression of fibroblast growth factors in rat dorsal root ganglion neurons and regulation after peripheral nerve injury
Handschin et al. Cbfa-1 (Runx-2) and osteocalcin expression by human osteoblasts in heparin osteoporosis in vitro
Chen et al. Interlukin-18 is a pivot regulatory factor on matrix metalloproteinase-13 expression and brain astrocytic migration